AKT1 and acute lymphoblastic leukemia: Within this context, it is reasonable to suggest that the combination of MAPK/ERK and PI3K/AKT inhibitors can affect the antioxidant systems, and therefore might have the potential to enhance anticancer effect in ALL and AML cells.